CBLB Deficiency in Human CD4+ T Cells Results in Resistance to T Regulatory Suppression through Multiple Mechanisms

Author:

Song Jing1ORCID,Anderson Warren23ORCID,Hu Alex4ORCID,Obata-Ninomiya Kazushige5ORCID,Ziegler Steven F.5,Rawlings David J.267,Buckner Jane H.1ORCID

Affiliation:

1. *Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA;

2. †Center for Immunity and Immunotherapies and the Program for Cell and Gene Therapy, Seattle Children’s Research Institute, Seattle, WA;

3. ‡Department of Pathology, University of Washington School of Medicine, Seattle, WA;

4. §Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA;

5. ¶Center for Fundamental Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA;

6. ‖Department of Pediatrics, University of Washington School of Medicine, Seattle, WA; and

7. #Department of Immunology, University of Washington School of Medicine, Seattle, WA

Abstract

Abstract Cbl-b is a negative regulator of T cell activation, and in murine models, a lack of Cblb results in resistance of T effector (Teff) cells to T regulatory (Treg) cells, a feature of T cells in many autoimmune diseases. Here, we used trackable gene editing approaches to knock out CBLB in primary human CD4+ T cells. We found that CBLB-knockout (CBLB-KO) CD4+ T cells were hyperproliferative and produced excessive amounts of IL-2. CBLB-KO CD4+ T cells were resistant to Treg suppression in vitro, which was partially reversed by blockade of IL-2. RNA-sequencing and puromycin incorporation assays demonstrated that CBLB-KO CD4+ T cells can overcome Treg suppression on the transcriptional and translational levels, resulting in the overproduction of cytokines to drive the proliferation and activation of Teff cells. These findings highlight a potential mechanism of Teff resistance in human autoimmune disease and the power of gene editing primary T cells to explore disease mechanisms.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3